On Nov. 7, Vipshop Holdings Limited (NYSE:VIPS) announced that it plans to release its third quarter 2014 financial results on Tuesday, November 18, 2014 after market close. The Company will hold a conference call on Wednesday, November 19, 2014 at 8:00 am Eastern Time or 9:00 pm Beijing Time to discuss the financial results. Vipshop Holdings Limited (NYSE:VIPS) belongs to Services sector. Its net profit margin is 3.50% and weekly performance is 7.22%. On last trading day company shares ended up $24.51. Vipshop Holdings Limited (NYSE:VIPS) distance from 50-day simple moving average (SMA50) is 20.24%. The Dow Chemical Company (NYSE:DOW)‘s stock had its “neutral” rating restated by analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Thursday. They currently have a $49.00 target price on the stock, down from their previous target price of $50.00. JPMorgan Chase & Co.’s price target would indicate a potential upside of 2.77% from the company’s current price. The Dow Chemical Company (NYSE:DOW) shares moved down -0.04% in last trading session and ended the day at $49.48. DOW Gross Margin is 17.60% and its return on assets is 5.20%. The Dow Chemical Company (NYSE:DOW) quarterly performance is -3.81%. On Nov 07, it was announced thatMagellan Midstream Partners LP (NYSE:MMP) is buying a 40-mile crude oil pipeline system from the company it jointly built with Occidental Petroleum Corp. Tulsa-based Magellan is purchasing Occidental’s 50 percent interest for $75 million and will own all of the system upon closing. The joint venture BridgeTex Pipeline Co. LLC is selling the 40-mile, 24-inch diameter line that moves crude oil from Magellan’s East Houston terminal to Texas City. On 10 November, Magellan Midstream Partners LP (NYSE:MMP) shares moved down -1.12% and was closed at $83.56. MMP EPS growth in last 5 year was 18.20%. Magellan Midstream Partners LP (NYSE:MMP) year to date (YTD) performance is 36.49%. On Nov. 6, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced financial results for the third quarter ended September 30, 2014. For the three months ended September 30, 2014, revenues increased to $3.2 million from $2.4 million in the third quarter of 2013. Increased collaboration revenue was associated with the National Institute of Allergy and Infectious Diseases (NIAID) contract to develop our broad spectrum antiviral, BCX4430, through Phase 1 clinical studies. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ended the last trading day at $11.16. Company weekly volatility is calculated as 9.00% and price to cash ratio as 6.06. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) showed a weekly performance of -2.53%. FelCor Lodging Trust Incorporated (NYSE:FCH) reported operating results for the third quarter ended September 30, 2014. Same-store RevPAR increased 12.3%; RevPAR for comparable core hotels increased 9.8%. Adjusted FFO per share improved to $0.21, a 50% increase from 2013. FelCor Lodging Trust Incorporated (NYSE:FCH) shares moved down -0.93% in last trading session and ended the day at $10.68. FCH Gross Margin is 63.90% and its return on assets is 1.10%. FelCor Lodging Trust Incorporated (NYSE:FCH) quarterly performance is 2.79%.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
